Tacrolimus targeted half-dose + Tacrolimus targeted plain dose

ApprovedUNKNOWN

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

De Novo Transplant Disease

Conditions

De Novo Transplant Disease

Trial Timeline

Jul 1, 2013 → Mar 1, 2015

NCT ID

NCT02154854

About Tacrolimus targeted half-dose + Tacrolimus targeted plain dose

Tacrolimus targeted half-dose + Tacrolimus targeted plain dose is a approved stage product being developed by Astellas Pharma for De Novo Transplant Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT02154854. Target conditions include De Novo Transplant Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02154854	Approved	UNKNOWN	Jul 1, 2013	Mar 1, 2015	De Novo Transplant Disease
NCT01744470	Approved	UNKNOWN	May 1, 2012	Mar 1, 2015	De Novo Transplant Disease

Competing Products

19 competing products in De Novo Transplant Disease

See all competitors

Product	Company	Stage	Hype Score
Alefacept + placebo + Tacrolimus + Mycophenolate Mofetil + Steroids	Astellas Pharma	Phase 2	52
Prograf + Advagraf	Astellas Pharma	Approved	85
ATG-F	Astellas Pharma	Approved	85
Advagraf + Prograf + Corticosteroid + Mycophenolate mofetil	Astellas Pharma	Approved	85
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose	Astellas Pharma	Approved	85
Venetoclax + Azacitidine + Cytarabine + Methotrexate + Hydrocortisone + Leucovorin + Dexamethasone + Vincristine + Doxorubicin + Dexrazoxane + Calaspargase Pegol + Erwinia asparaginase	AbbVie	Phase 1	33
Birabresib Dose 20 mg	Merck	Phase 1	33
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Phase 3	77
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Approved	85
Enteric-Coated Mycophenolate Sodium (EC-MPS)	Novartis	Approved	85
everolimus + cyclosporine + Prednison (continuous steroids)	Novartis	Phase 3	77
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Phase 3	77
AEB071	Novartis	Phase 1	33
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	77
EC-MPS	Novartis	Phase 3	77
Enteric-coated Mycophenolate sodium (EC-MPS), valsartan	Novartis	Phase 3	77
everolimus	Novartis	Phase 3	77
Prograf + Tacrolimus Hexal	Novartis	Approved	85
Mycophenolate Mofetil	Roche	Approved	85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved